TTK inhibitors as a targeted therapy for CTNNB1 (β-catenin) mutant cancers
Zaman, Guido J.R., de Roos, Jeroen A.D.M., Libouban, Marion A.A., Prinsen, Martine B.W., de Man, Jos, Buijsman, Rogier C., Uitdehaag, Joost C.M.Language:
english
Journal:
Molecular Cancer Therapeutics
DOI:
10.1158/1535-7163.mct-17-0342
Date:
July, 2017
File:
PDF, 7.33 MB
english, 2017